Trial Profile
Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter/Multinational, Efficacy and Safety Study of Desloratadine 5 mg in the Treatment of Subjects With Allergic Rhinitis Who Meet the Criteria for Intermittent Allergic Rhinitis (IAR).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Feb 2022
Price :
$35
*
At a glance
- Drugs Desloratadine (Primary)
- Indications Allergic rhinitis
- Focus Therapeutic Use
- Acronyms ACCEPT-1
- Sponsors Schering-Plough
- 13 Jun 2019 Trial has been completed in Spain.
- 01 Oct 2009 Results published in Allergy.
- 17 Mar 2009 Primary endpoint 'Total 5 symptom score' has been met.